{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:39:16Z","timestamp":1791646756739,"version":"4.3.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Synlogic, Inc."},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To assess whether 24-h urine oxalate (UOx) excretion is a risk factor for incident chronic kidney disease (CKD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This longitudinal observational USA-based study included 426 896 individuals aged \u226518\u00a0years with no CKD at baseline and with at least one UOx, and at least 6\u00a0months of baseline and 6\u00a0months of follow-up data. Of these, 11 239 (2.6%) had an underlying malabsorptive condition. Incident CKD, defined by relevant International Classification of Diseases codes, was identified from a multi-source data cloud containing individual-level healthcare claims and electronic medical records data. The association between categories of UOx and incident CKD was modeled using logistic regression adjusting for age, sex, race, body mass index, baseline urine calcium, urine citrate, urine volume, tobacco use, hypertension, diabetes, malabsorption and cardiovascular disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean follow-up time was 38.9\u00a0months (standard deviation 21.7). Compared with individuals with UOx &amp;lt;20\u00a0mg\/24\u00a0h, the odds of developing incident CKD increased for UOx 20\u201329\u00a0mg\/24\u00a0h [multivariable-adjusted odds ratio (MVOR) 1.14 (95% CI 1.07, 1.21)] through 80+\u00a0mg\/24\u00a0h [MVOR 1.35 (1.21, 1.50)] and was statistically significant for each UOx category. A similar pattern was seen in the subgroup with a malabsorptive condition though the magnitudes of association were larger, with the odds of developing incident CKD increased for UOx 20\u201329\u00a0mg\/24\u00a0h [MVOR 1.50 (1.03, 2.20)] through 80+\u00a0mg\/24\u00a0h [MVOR 2.34 (1.50, 3.63)] as compared with UOx &amp;lt;20\u00a0mg\/24\u00a0h.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The risk of incident CKD increases with increasing 24-h UOx excretion. Future studies should examine whether reducing UOx diminishes the risk of developing CKD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfad221","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:25:02Z","timestamp":1696677902000},"page":"788-794","source":"Crossref","is-referenced-by-count":8,"title":["Twenty-four-hour urine oxalate and risk of chronic kidney disease"],"prefix":"10.1093","volume":"39","author":[{"given":"Marja","family":"Puurunen","sequence":"first","affiliation":[{"name":"Synlogic Therapeutics , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Synlogic Therapeutics , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Synlogic Therapeutics , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Mulder","sequence":"additional","affiliation":[{"name":"OM1, Inc., \u00a0 Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Wood","sequence":"additional","affiliation":[{"name":"University of Alabama , Birmingham, AL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Swenson","sequence":"additional","affiliation":[{"name":"OM1, Inc., \u00a0 Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Curhan","sequence":"additional","affiliation":[{"name":"OM1, Inc., \u00a0 Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"2025030500421332900_bib1","author":"Centers for Disease Control and Prevention Chronic Kidney Disease in the United States","year":"2021"},{"key":"2025030500421332900_bib2","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"The global burden of chronic kidney disease","volume":"395","author":"Cockwell","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2025030500421332900_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/MNH.0000000000000515","article-title":"Urinary oxalate as a potential mediator of kidney disease in diabetes mellitus and obesity","volume":"28","author":"Efe","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025030500421332900_bib4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet North Am Ed"},{"key":"2025030500421332900_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.ajkd.2008.11.019","article-title":"Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention","volume":"53","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2025030500421332900_bib6","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2215\/CJN.17541120","article-title":"The continuum of acid stress","volume":"16","author":"Wesson","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025030500421332900_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"2025030500421332900_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.08000520","article-title":"Pathophysiology and treatment of enteric hyperoxaluria","volume":"16","author":"Witting","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025030500421332900_bib9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1159\/000520286","article-title":"Clinical Outcomes and histological patterns in oxalate nephropathy due to enteric and nonenteric risk factors","volume":"52","author":"Reddy","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025030500421332900_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5527\/wjn.v3.i4.122","article-title":"Nephropathy in dietary hyperoxaluria: a potentially preventable acute or chronic kidney disease","volume":"3","author":"Glew","year":"2014","journal-title":"World J Nephrol"},{"key":"2025030500421332900_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.soard.2005.07.002","article-title":"Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass","volume":"1","author":"Nelson","year":"2005","journal-title":"Surg Obes Relat Dis"},{"key":"2025030500421332900_bib12","doi-asserted-by":"crossref","first-page":"e5287","DOI":"10.1136\/bmj.e5287","article-title":"Alberta Kidney Disease Network. Kidney stones and kidney function loss: a cohort study","volume":"345","author":"Alexander","year":"2012","journal-title":"BMJ"},{"key":"2025030500421332900_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/ki.2013.207","article-title":"NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy","volume":"84","author":"Knauf","year":"2013","journal-title":"Kidney Int"},{"key":"2025030500421332900_bib14","first-page":"2673","article-title":"Dietary oxalate intake and kidney outcomes","volume-title":"Nutrients","author":"Bargagli","year":"2020"},{"key":"2025030500421332900_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamainternmed.2018.7980","article-title":"Association of urinary oxalate excretion with the risk of chronic kidney disease progression","volume":"179","author":"Waikar","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025030500421332900_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1523-1755.2001.00462.x","article-title":"Phenotypic expression of primary hyperoxaluria: comparative features of types I and II","volume":"59","author":"Milliner","year":"2001","journal-title":"Kidney Int"},{"key":"2025030500421332900_bib17","doi-asserted-by":"crossref","first-page":"F785","DOI":"10.1152\/ajprenal.00488.2015","article-title":"Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL\/6 mice","volume":"310","author":"Mulay","year":"2016","journal-title":"Am J Physiol Ren Physiol"},{"key":"2025030500421332900_bib18","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.juro.2013.02.3229","article-title":"Steatorrhea and hyperoxaluria occur after gastric bypass surgery in obese rats regardless of dietary fat or oxalate","volume":"190","author":"Canales","year":"2013","journal-title":"J Urol"},{"key":"2025030500421332900_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.urology.2012.02.052","article-title":"Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery","volume":"80","author":"Pang","year":"2012","journal-title":"Urology"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad221\/52302835\/gfad221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/5\/788\/59935324\/gfad221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/39\/5\/788\/59935324\/gfad221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:42:32Z","timestamp":1741135352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/39\/5\/788\/7296155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10,6]]},"published-print":{"date-parts":[[2024,4,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad221","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,10,6]]}}}